stockrow
Saturday 7 November 2026
Export ENLV’s income statement to Excel — free account
Enlivex Ltd.
ENLV Healthcare Biotechnology
- EPS
- +5,349.9%
- Free cash flow
- +35.9%
Quarter to June 2026, against a year earlier
1.27
0.00
0.00%
Follow ENLV
Alert me
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
Current Ratio |
193.24 | 6.84 | 5.57 | 7.92 | 18.32 | 8.72 | 2.75 | 9.09 | 13.09 | 5.46 |
Net Debt/EBITDA |
118.29 | 1.51 | 0.96 | 1.84 | 4.20 | 3.83 | 1.57 | 1.89 | 4.31 | 0.62 |
Debt/Assets |
0.02% | 1.08% | 0.00% | 6.20% | 5.66% | 1.24% | 1.70% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.01 | 0.00 | 0.07 | 0.06 | 0.01 | 0.03 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
(0.01) | 0.87 | 0.81 | 0.77 | 1.21 | 0.93 | 0.75 | 0.65 | 0.72 | 0.97 |
Capex/Depreciation |
(0.20) | 0.15 | (0.12) | (10.45) | (2.98) | (3.56) | (0.92) | (3.81) | (1.57) | (0.47) |
Interest Coverage |
— | — | — | (30.89) | (3.38) | (43.49) | (8.59) | (1,766.33) | (5.87) | (176.29) |
| 126.17% | (55.95%) | (66.88%) | (43.78%) | (24.01%) | (50.56%) | (91.71%) | (56.96%) | (38.50%) | (120.33%) | |
| 104.94% | (46.54%) | (55.65%) | (38.16%) | (21.35%) | (40.83%) | (65.64%) | (47.64%) | (31.93%) | (102.88%) | |
ROIC |
(4.78%) | (2,533.16%) | (664.68%) | (149.41%) | (191.41%) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
71.23% | (65.80%) | (99.40%) | (55.87%) | (17.17%) | (33.56%) | (84.62%) | (49.85%) | (36.57%) | (184.56%) |
Average Days of Receivables |
— | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Free Cash Flow per Share |
(55.03) | (151.19) | (305.25) | (418.19) | (257.28) | (219.05) | (200.28) | (248.08) | (170.21) | (9,120.00) |
Cash per Share |
9,127.65 | 274.81 | 352.97 | 655.07 | 1,129.26 | 671.73 | 374.18 | 669.59 | 629.72 | 5,810.59 |
Shareholders Equity per Share |
10,157.21 | 275.89 | 388.68 | 741.08 | 1,141.46 | 646.39 | 312.52 | 664.79 | 593.92 | 5,117.06 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
10,157.21 | 275.89 | 388.68 | 741.08 | 1,141.46 | 646.39 | 312.52 | 664.79 | 593.92 | 5,117.06 |
Free Cash Flow |
(10.48) | (12.93) | (23.63) | (32.07) | (19.17) | (12.03) | (7.23) | (3.62) | (2.43) | (15.50) |
Working Capital |
1,734.16 | 22.19 | 27.70 | 45.72 | 81.72 | 33.75 | 10.44 | 9.15 | 8.42 | 8.61 |
Capital Expenditures |
(0.07) | 0.08 | (0.10) | (8.12) | (1.62) | (1.02) | (0.19) | (0.46) | (0.13) | (0.02) |
Net Current Asset Value |
1,351.13 | 21.90 | 27.02 | 41.53 | 76.34 | 33.25 | 10.14 | 8.95 | 8.07 | 8.61 |
| Other line items | ||||||||||
Quick Ratio |
192.75 | 6.18 | 4.51 | 7.60 | 17.83 | 8.44 | 2.59 | 8.84 | 13.07 | 5.46 |
Depreciation/Fixed assets |
0.92 | 0.87 | 0.54 | 0.08 | 0.22 | 0.19 | 0.32 | 0.18 | 0.21 | 0.54 |
Cash ROIC |
(0.29%) | (27.28%) | (41.16%) | (28.82%) | (10.98%) | (16.50%) | (28.82%) | (18.59%) | (13.91%) | (83.46%) |
Accounts Receivable Turnover |
— | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(54.68) | (152.14) | (303.91) | (312.29) | (235.46) | (200.49) | (195.04) | (216.51) | (161.12) | (9,109.41) |
Capex per Share |
(0.35) | 0.95 | (1.33) | (105.89) | (21.81) | (18.56) | (5.24) | (31.58) | (9.09) | (10.59) |
Average Receivables |
— | — | — | — | — | — | 1.11 | 0.15 | 0.38 | 0.86 |
Average Payables |
2.31 | 0.82 | 1.39 | 1.41 | 0.67 | 0.39 | 0.24 | 0.11 | 0.37 | 1.06 |
Average Assets |
1,177.34 | 32.26 | 52.24 | 81.39 | 67.75 | 28.96 | 14.30 | 10.29 | 10.09 | 15.57 |
Average Common Equity |
979.27 | 26.84 | 43.46 | 70.94 | 60.26 | 23.38 | 10.23 | 8.61 | 8.36 | 13.32 |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 2 Nov 2026